228 related articles for article (PubMed ID: 36184945)
1. Neurochemical, histological, and behavioral profiling of the acute, sub-acute, and chronic MPTP mouse model of Parkinson's disease.
Santoro M; Fadda P; Klephan KJ; Hull C; Teismann P; Platt B; Riedel G
J Neurochem; 2023 Jan; 164(2):121-142. PubMed ID: 36184945
[TBL] [Abstract][Full Text] [Related]
2. alpha-Synuclein- and MPTP-generated rodent models of Parkinson's disease and the study of extracellular striatal dopamine dynamics: a microdialysis approach.
Bazzu G; Calia G; Puggioni G; Spissu Y; Rocchitta G; Debetto P; Grigoletto J; Zusso M; Migheli R; Serra PA; Desole MS; Miele E
CNS Neurol Disord Drug Targets; 2010 Aug; 9(4):482-90. PubMed ID: 20522009
[TBL] [Abstract][Full Text] [Related]
3. Brain Selective Estrogen Treatment Protects Dopaminergic Neurons and Preserves Behavioral Function in MPTP-induced Mouse Model of Parkinson's Disease.
Thadathil N; Xiao J; Hori R; Alway SE; Khan MM
J Neuroimmune Pharmacol; 2021 Sep; 16(3):667-678. PubMed ID: 33221984
[TBL] [Abstract][Full Text] [Related]
4. Restorative effect of endurance exercise on behavioral deficits in the chronic mouse model of Parkinson's disease with severe neurodegeneration.
Pothakos K; Kurz MJ; Lau YS
BMC Neurosci; 2009 Jan; 10():6. PubMed ID: 19154608
[TBL] [Abstract][Full Text] [Related]
5. 1-Methyl-4-phenyl-1,2,3,6 tetrahydropyridine/probenecid impairs intestinal motility and olfaction in the early stages of Parkinson's disease in mice.
Choi JG; Huh E; Ju IG; Kim N; Yun J; Oh MS
J Neurol Sci; 2018 Sep; 392():77-82. PubMed ID: 30031172
[TBL] [Abstract][Full Text] [Related]
6. Combining nitric oxide release with anti-inflammatory activity preserves nigrostriatal dopaminergic innervation and prevents motor impairment in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease.
L'Episcopo F; Tirolo C; Caniglia S; Testa N; Serra PA; Impagnatiello F; Morale MC; Marchetti B
J Neuroinflammation; 2010 Nov; 7():83. PubMed ID: 21092260
[TBL] [Abstract][Full Text] [Related]
7. Social enrichment attenuates nigrostriatal lesioning and reverses motor impairment in a progressive 1-methyl-2-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of Parkinson's disease.
Goldberg NR; Fields V; Pflibsen L; Salvatore MF; Meshul CK
Neurobiol Dis; 2012 Mar; 45(3):1051-67. PubMed ID: 22198503
[TBL] [Abstract][Full Text] [Related]
8. Modeling a sensitization stage and a precipitation stage for Parkinson's disease using prenatal and postnatal 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administration.
Muthian G; Mackey V; King J; Charlton CG
Neuroscience; 2010 Sep; 169(3):1085-93. PubMed ID: 20540993
[TBL] [Abstract][Full Text] [Related]
9. Systemically administered neuregulin-1β1 rescues nigral dopaminergic neurons via the ErbB4 receptor tyrosine kinase in MPTP mouse models of Parkinson's disease.
Depboylu C; Rösler TW; de Andrade A; Oertel WH; Höglinger GU
J Neurochem; 2015 May; 133(4):590-7. PubMed ID: 25581060
[TBL] [Abstract][Full Text] [Related]
10. Pyruvate Prevents Dopaminergic Neurodegeneration and Motor Deficits in the 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine Model of Parkinson's Disease.
Kim YM; Choi SY; Hwang O; Lee JY
Mol Neurobiol; 2022 Nov; 59(11):6956-6970. PubMed ID: 36057709
[TBL] [Abstract][Full Text] [Related]
11. The intranasal administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): a new rodent model to test palliative and neuroprotective agents for Parkinson's disease.
Prediger RD; Aguiar AS; Moreira EL; Matheus FC; Castro AA; Walz R; De Bem AF; Latini A; Tasca CI; Farina M; Raisman-Vozari R
Curr Pharm Des; 2011; 17(5):489-507. PubMed ID: 21375482
[TBL] [Abstract][Full Text] [Related]
12. Quantitative assessment of gait and neurochemical correlation in a classical murine model of Parkinson's disease.
Wang XH; Lu G; Hu X; Tsang KS; Kwong WH; Wu FX; Meng HW; Jiang S; Liu SW; Ng HK; Poon WS
BMC Neurosci; 2012 Nov; 13():142. PubMed ID: 23151254
[TBL] [Abstract][Full Text] [Related]
13. Reduced dopaminergic neuron degeneration and global transcriptional changes in Parkinson's disease mouse brains engrafted with human neural stems during the early disease stage.
Pereira MCL; Boese AC; Murad R; Yin J; Hamblin MH; Lee JP
Exp Neurol; 2022 Jun; 352():114042. PubMed ID: 35271839
[TBL] [Abstract][Full Text] [Related]
14. Effects of blocking the dopamine biosynthesis and of neurotoxic dopamine depletion with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on voluntary wheel running in mice.
Leng A; Mura A; Hengerer B; Feldon J; Ferger B
Behav Brain Res; 2004 Oct; 154(2):375-83. PubMed ID: 15313025
[TBL] [Abstract][Full Text] [Related]
15. Lack of long-term changes in circadian, locomotor, and cognitive functions in acute and chronic MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) mouse models of Parkinson's disease.
Fifel K; Dkhissi-Benyahya O; Cooper HM
Chronobiol Int; 2013 Jul; 30(6):741-55. PubMed ID: 23758587
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic activation of autophagy by combined treatment with rapamycin and trehalose in a mouse MPTP-induced model of Parkinson's disease.
Pupyshev AB; Tikhonova MA; Akopyan AA; Tenditnik MV; Dubrovina NI; Korolenko TA
Pharmacol Biochem Behav; 2019 Feb; 177():1-11. PubMed ID: 30582934
[TBL] [Abstract][Full Text] [Related]
17. Dopamine receptor D2 on CD4
Liu Z; Zhai XR; Du ZS; Xu FF; Huang Y; Wang XQ; Qiu YH; Peng YP
Brain Behav Immun; 2021 Nov; 98():110-121. PubMed ID: 34403737
[TBL] [Abstract][Full Text] [Related]
18. Pain perception in acute model mice of Parkinson's disease induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).
Park J; Lim CS; Seo H; Park CA; Zhuo M; Kaang BK; Lee K
Mol Pain; 2015 May; 11():28. PubMed ID: 25981600
[TBL] [Abstract][Full Text] [Related]
19. Intervention with exercise restores motor deficits but not nigrostriatal loss in a progressive MPTP mouse model of Parkinson's disease.
Sconce MD; Churchill MJ; Greene RE; Meshul CK
Neuroscience; 2015 Jul; 299():156-74. PubMed ID: 25943481
[TBL] [Abstract][Full Text] [Related]
20. Nanomicellar formulation of coenzyme Q10 (Ubisol-Q10) effectively blocks ongoing neurodegeneration in the mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model: potential use as an adjuvant treatment in Parkinson's disease.
Sikorska M; Lanthier P; Miller H; Beyers M; Sodja C; Zurakowski B; Gangaraju S; Pandey S; Sandhu JK
Neurobiol Aging; 2014 Oct; 35(10):2329-46. PubMed ID: 24775711
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]